Miguel Perez-Pinzon, Ph.D., FAHA, Chair, International Stroke Conference 2019 Program Committee, offers overviews and perspective on late breaking science being presented at ISC 2019 in Honolulu.  He is Professor of Neurology/Neuroscience, Director, Cerebral Vascular Disease Research Center, Director, Peritz Scheinberg Cerebral Vascular Laboratory, Vice-Chair for Neurology Basic Science at the Miller School of Medicine, Department of Neurology at the University of Miami, Miami, FL.

copyright American Heart Association

"There are few messages here. Number one is, the Furoxime has been shown in animal models to be highly beneficial, so the expectation is that it will also work in patients because its a simple compound. It's a compound that eliminates iron from blood that is degrading. So I think the message here is for safety. What's the safety? They realize that a high dosages is not beneficial, actually to be harmful. But lower dosages is safe and the benefits."